• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 1, 2017

View Archived Issues

Earnings

Corcept Therapeutics Inc., of Menlo Park, Calif., reported 2016 revenue of $81.3 million, up 62 percent over the same quarter in 2015, from sales of Cushing's syndrome drug Korlym (mifepristone). Read More

In the clinic

Tigenix NV, of Leuven, Belgium, said the first patient was enrolled and treated in its phase Ib/IIa trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia. Cx611 is an intravenously administered product of allogeneic expanded adipose-derived stem cells. Read More

Appointments and advancements

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., appointed Richard Peters President and CEO, effective Feb. 6. Read More

Other news to note

Exelixis Inc., South San Francisco, and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, have signed an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis' lead oncology medicine. Read More

Financings

Rigel Pharmaceuticals Inc., of South San Francisco, said it priced its public offering of 20 million shares of common stock at $2 apiece for gross proceeds of about $40 million. Rigel granted underwriters a 30-day option to purchase up to an aggregate of 3 million additional shares, which would bring in as much as $6 million more. Read More

Newly retooled Realm advancing lead drug as immunomodulator

LONDON – Following a total corporate makeover and a revamp of its technology, Realm Therapeutics plc has announced its rebirth with the filing of an FDA investigational new drug application (IND) for a phase II study of its lead product, PRO22, in atopic dermatitis and a promise to start a second phase II, in allergic conjunctivitis, later this year. Read More

PCR below par? Recurring C. diff may trick gene test; Seres queries FDA on path

Science stands "at the very beginning of understanding the complexity" of the gut microbiome, Synthetic Biologics Inc. CEO Jeffrey Riley told BioWorld Today, noting that his company engages in "more traditional drug discovery and development vs. what Seres [Therapeutics Inc.] is doing, which is more on the cutting edge" – an edge where complexity can take its toll. And did. Read More

Phase III failure for heart surgery drug crashes Tenax shares

Shares of Tenax Therapeutics Inc. (NASDAQ:TENX) fell 76.4 percent to 46 cents by Tuesday's close on news that its lead candidate, levosimendan, failed to meet the co-primary endpoints of a phase III study evaluating its potential for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), an indication for which it had been granted FDA fast track status. Read More

Drug pricing mayhem moves to court over rising insulin charges

Now, the lawyers are involved. Read More

Biopharma goes to the White House, talks pricing, regulations, jobs

In his first official meeting with the biopharma industry, President Donald Trump repeatedly delivered a clear message: Get U.S. drug prices down. Way down. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe